nejm semaglutide heart failure obesity #clinicaltrials #medicalresearch Semaglutide ameliorates pressure overload-induced cardiac

Medicines that mimic or enhance these hormones have become increasingly important in managing type 2 diabetes and, more recently, obesity

Certain peptides can boost metabolism and aid in fat loss, helping individuals achieve their weight loss goals more effectively

Notably, the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, the first dedicated kidney outcome trial evaluating canagliflozin in people with type 2 diabetes mellitus and CKD, demonstrated a substantial reduction in the risk of kidney events [46]

How would the initial evaluation be different for patients who have a new diagnosis of atrial fibrillation compared to those who have a known prior history of this arrhythmia